Clinical Failure (children with a severe to moderate overall clinical assessment score at two hours) · patients with acute asthma
IV + inhaled beta agonist probably leads to lower clinical Failure (children with a severe to moderate overall… compared with inhaled beta‐agonist (moderate certainty).
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported symptom score  · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events  · adults and children with cystic fibrosis
1 finding from 1 review
FVC (% predicted) Change from baseline · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum: volume · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQoL ‐ all domains (change from baseline) Scale: age‐appropriate versions of the CFQ‐R questionnaire · adults, children and young people with CF
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · adults, children and young people with CF
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · adults, children and young people with CF
1 finding from 1 review
FVC · adults, children and young people with CF
1 finding from 1 review
Lung function: FEF25‐75 mL/s (change from baseline) · adults, children and young people with CF
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults, children and young people with CF
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · Neonates with developing BPD
Inhaled steroids showed no clear difference in death or BPD at 36 weeks' postmenstrual age compared with systemic steroids (moderate certainty).
2 findings from 1 review
Diastolic blood pressure > 95th percentile at 7 years · Neonates with developing BPD
Inhaled steroids probably leads to lower diastolic blood pressure > 95th percentile at 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Ever diagnosed as asthmatic by 7 years · Neonates with developing BPD
Inhaled steroids showed no clear difference in ever diagnosed as asthmatic by 7 years compared with systemic steroids (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Neonates with developing BPD
Inhaled steroids showed no clear difference in BPD at 36 weeks' postmenstrual age compared with systemic steroids (low certainty).
1 finding from 1 review
Hyperglycaemia · Neonates with developing BPD
Inhaled steroids showed no clear difference in hyperglycaemia compared with systemic steroids (low certainty).
1 finding from 1 review
Hypertension · Neonates with developing BPD
Inhaled steroids may leads to lower hypertension compared with systemic steroids (low certainty).
1 finding from 1 review